Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Comparative Efficacy and Safety of Combined Radiotherapy and Adjuvant Hormone Therapy (Leuprorelin SR 11.25 mg) and Hormone Therapy Alone (Leuprorelin SR 11.25 mg) in Locally Advanced Prostate Cancer (T3-T4 or pT3 on Biopsy, N0, M0)

NCT01122121 is registered in ClinicalTrials.gov with Takeda as lead sponsor.

NCT NCT01122121
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01122121 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Comparative Efficacy and Safety of Combined Radiotherapy and Adjuvant Hormone Therapy (Leuprorelin SR 11.25 mg) and Hormone Therapy Alone (Leuprorelin SR 11.25 mg) in Locally Advanced Prostate Cancer (T3-T4 or pT3 on Biopsy, N0, M0)
Lead sponsor
Takeda
Phase
Phase 3
Overall status
Completed
Start date
March 31, 2000
Completion date
June 30, 2009
Enrollment
273 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

prostatic neoplasms, locally advanced